Skip to main content
Clinical Trials/ISRCTN18181860
ISRCTN18181860
Completed
未知

Seroprevalence of SARS-CoV-2 antibodies and development of immunity in the Swiss population – Multicenter population-based observational studies to inform policy making

Swiss School of Public Health0 sites28,000 target enrollmentJuly 13, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Swiss School of Public Health
Enrollment
28000
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2020 Results article in https://www.doi.org/10.1016/S0140-6736(20)31304-0 early results (added 09/07/2020) 2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33098441/ protocol (added 26/10/2020) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35296242/ Seroprevalence and attitudes of care home and in-home care staff (added 18/03/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35725472/ Results from the Swiss national seroprevalence study Corona Immunitas (added 21/06/2022) 2023 Results article in https://doi.org/10.1016/j.clnu.2023.04.007 Association of plasma zinc levels with anti-SARS-CoV-2 IgG and IgA seropositivity in the general population: A case-control study (added 03/05/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37257891/ Recovery and symptom trajectories up to 2 years after SARS-CoV-2 infection (added 01/06/2023) 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/35295967/ Protocol and initial results of Corona Immunitas Digital Follow-Up eCohort (added 29/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37025205/ Association between serologically confirmed COVID-19 infection and cognitive functioning in community dwelling older adults (added 29/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36959642/ Changes in socioeconomic resources and mental health after the second COVID-19 wave (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35929427/ Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35611352/ Impact of screen time and green time on mental health in children and adolescents during the COVID-19 pandemic (added 29/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37149211/ Longitudinal humoral and cell-mediated immune responses (added 29/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36631745/ Prevalence and association of frailty with SARS-CoV-2 infection in older adults (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36187688/ SARS-CoV-2 infection among employees working from home and on site (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35019254/ SARS-CoV-2 seroprevalence and COVID-19 disease among people on opioid agonist treatment (added 29/08/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36870034/ Seroprevalence trends of anti-SARS-CoV-2 antibodies and associated risk factors (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35381519/ Trajectories of depression, anxiety and stress during the pandemic (added 29/08/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35418817/ Vaccination intention, beliefs, attitudes, and trust (added 29/08/2023)

Registry
who.int
Start Date
July 13, 2020
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Observational

Investigators

Sponsor
Swiss School of Public Health

Eligibility Criteria

Inclusion Criteria

  • 1\. No acute SARS\-CoV\-2 infection: no presence of symptoms for at least 48 hours
  • 2\. In case of a SARS\-CoV\-2 infection verified by a RT\-PCR test, the earliest inclusion is 21 days after the test date

Exclusion Criteria

  • 1\. No informed consent
  • 2\. Suspicion of acute COVID\-19 infection

Outcomes

Primary Outcomes

Not specified

Similar Trials